{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:22:31Z","timestamp":1766514151005,"version":"3.37.3"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We analyzed data from 2012 to 2016 for patients who were hospitalized or who died after \u22651 dose of isoniazid-rifapentine for treatment of latent Mycobacterium tuberculosis infection. No patients died; 15 were hospitalized. Nine patients experienced hypotension, and 5 had elevated serum aminotransferases, reinforcing the need for vigilant monitoring during treatment.<\/jats:p>","DOI":"10.1093\/cid\/ciaa286","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T20:33:12Z","timestamp":1584390792000},"page":"2502-2505","source":"Crossref","is-referenced-by-count":3,"title":["Analysis of Severe Adverse Events Reported Among Patients Receiving Isoniazid-Rifapentine Treatment for Latent <i>Mycobacterium tuberculosis<\/i> Infection\u2014United States, 2012\u20132016"],"prefix":"10.1093","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2616-8736","authenticated-orcid":false,"given":"Kristine M","family":"Schmit","sequence":"first","affiliation":[{"name":"Division of Tuberculosis (TB) Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M","family":"Wortham","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis (TB) Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine S","family":"Ho","sequence":"additional","affiliation":[{"name":"Division of Global Human Immunodeficiency Virus and TB, Centers for Disease Control and Prevention , Atlanta, Georgia,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista M","family":"Powell","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention , Atlanta, Georgia,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,3,18]]},"reference":[{"key":"2024111411413227300_CIT0001","doi-asserted-by":"crossref","first-page":"e0140881","DOI":"10.1371\/journal.pone.0140881","article-title":"Tuberculosis infection in the united states: prevalence estimates from the national health and nutrition examination survey, 2011\u20132012","volume":"10","author":"Miramontes","year":"2015","journal-title":"PLoS One"},{"key":"2024111411413227300_CIT0002","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/oxfordjournals.aje.a121593","article-title":"The prognosis of a positive tuberculin reaction in childhood and adolescence","volume":"99","author":"Comstock","year":"1974","journal-title":"Am J Epidemiol"},{"key":"2024111411413227300_CIT0003","doi-asserted-by":"crossref","first-page":"e0153728","DOI":"10.1371\/journal.pone.0153728","article-title":"Recent transmission of tuberculosis: United States, 2011\u20132014","volume":"11","author":"Yuen","year":"2016","journal-title":"PLoS One"},{"key":"2024111411413227300_CIT0004","first-page":"1","article-title":"Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America","volume":"54","author":"Taylor","year":"2005","journal-title":"MMWR Recomm Rep"},{"issue":"RR-6","key":"2024111411413227300_CIT0005","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"49","author":"Centers for Disease Control and Prevention.","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"2024111411413227300_CIT0006","first-page":"1650","article-title":"Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection","volume":"60","author":"Centers for Disease Control and Prevention.","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024111411413227300_CIT0007","doi-asserted-by":"crossref","first-page":"723","DOI":"10.15585\/mmwr.mm6725a5","article-title":"Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection","volume":"67","author":"Borisov","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024111411413227300_CIT0008","first-page":"289","article-title":"Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection \u2014 New York, and Georgia, 2000","volume":"50","author":"Centers for Disease Control and Prevention.","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rpt"},{"key":"2024111411413227300_CIT0009","first-page":"735","article-title":"Update: adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection\u2014United States, 2003","volume":"52","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rpt"},{"key":"2024111411413227300_CIT0010","first-page":"224","article-title":"Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection\u2014United States, 2004\u20132008","volume":"59","author":"Centers for Disease Control and Prevention.","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rpt"},{"key":"2024111411413227300_CIT0011","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/cid\/cix505","article-title":"High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent Mycobacterium tuberculosis infection","volume":"65","author":"Sandul","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024111411413227300_CIT0012","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of once-weekly rifapentine and isoniazid for M. tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2024111411413227300_CIT0013","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.5588\/ijtld.14.0829","article-title":"Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI","volume":"19","author":"Bliven-Sizemore","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024111411413227300_CIT0014","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/pds.4423","article-title":"A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection","volume":"27","author":"Pease","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa286\/33166793\/ciaa286.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/71\/9\/2502\/34676612\/ciaa286.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/71\/9\/2502\/34676612\/ciaa286.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T12:34:38Z","timestamp":1731587678000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/9\/2502\/5809293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,18]]},"references-count":14,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,3,18]]},"published-print":{"date-parts":[[2020,12,3]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa286","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"type":"print","value":"1058-4838"},{"type":"electronic","value":"1537-6591"}],"subject":[],"published-other":{"date-parts":[[2020,11,1]]},"published":{"date-parts":[[2020,3,18]]}}}